目的 探讨基因治疗联合化疗治疗肺癌胸腔积液临床效果及安全性.方法 选取肺癌胸腔积液患者180例,对照组患者采用顺铂+多西紫杉醇化疗治疗;联合治疗组患者加用重组人p53腺病毒注射液;比较两组患者治疗效果;结果 联合治疗组总有效率明显高于对照组;患者咳嗽、疲乏、恶心呕吐、白细胞水平等均明显优于对照组;高热发生率明显高于对照组;两组患者胸痛、食欲减退等临床症状改善率组间比较无显著差异;结论 基因治疗联合化疗治疗肺癌胸腔积液能够有效改善临床症状,延缓疾病进展,减少不良反应发生.%Objective To investigate the therapeutic effect and security of gene therapy combined with chemotherapy in the treatment of malignant pleural effusion caused by lung carcinoma. Methods 180 patients with pleural effusion of lung cancer were randomly divided into two groups. All patients were given cisplatin plus docetaxel chemotherapy, and the treatment group was additionally treated with recombinant human p53 adenovirus injection. The curative effect was compared between the two groups. Results The total effective rate was significantly higher in the treatment group than in the control group. The improvement of cough, fatigue, nausea and vomiting, and leukocyte level was more pronounced in the treatment group than in the control group. There was no significant difference on chest pain and anorexia between the two groups. Conclusion Gene therapy combined with chemotherapy can efficiently improve the clinical symptoms , slow the disease progression, and reduce the risk of adverse effects in the treatment of malignant pleural effusion caused by lung carcinoma.
展开▼
